Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Orlistat--a novel weight loss therapy.

K H Lucas1, B Kaplan-Machlis

  • 1Department of Clinical Pharmacy, West Virginia University, Charleston, USA. klucas@hsc.wvu.edu

The Annals of Pharmacotherapy
|March 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction.

The Annals of pharmacotherapy·2001
Same author

Lysine for management of herpes labialis.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same author

Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.

Archives of family medicine·2000
Same author

More about orlistat.

Pharmacotherapy·2000
Same author

Shaking, chills, and rigors with once-daily gentamicin.

Pharmacotherapy·1999
Same author

Therapeutic uses of vitamin E in prevention of atherosclerosis.

Alternative medicine review : a journal of clinical therapeutic·1999

Orlistat, a lipase inhibitor, aids weight loss by reducing dietary fat absorption. It

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Obesity Treatment

Background:

  • Obesity is a significant public health concern requiring effective pharmacotherapies.
  • Orlistat represents a novel therapeutic approach as the first lipase inhibitor for obesity management.

Purpose of the Study:

  • To comprehensively review orlistat's pharmacology, pharmacokinetics, safety, efficacy, and therapeutic applications in obesity treatment.
  • To evaluate drug interactions and clinical considerations for orlistat use.

Main Methods:

  • Systematic review of English-language literature from 1966 to July 2000, including MEDLINE, drug manufacturer data, and official health organization websites.
  • Selection of prospective, randomized, double-blind, placebo-controlled human trials for detailed analysis.

Related Experiment Videos

Main Results:

  • Orlistat inhibits dietary fat absorption by approximately 30%, leading to weight reduction.
  • Clinical trials demonstrate orlistat's efficacy and safety, with primarily gastrointestinal side effects.
  • Orlistat can impede fat-soluble vitamin absorption, necessitating daily multivitamin supplementation.

Conclusions:

  • Orlistat provides a new treatment option for weight loss and maintenance by blocking fat absorption.
  • Orlistat may benefit obese patients with comorbidities like diabetes and hyperlipidemia.
  • Orlistat is a valuable adjunctive therapy for weight management in individuals committed to lifestyle changes.